Home›Rheumatology› Stigma affects nearly half of adults with SLE, pooled prevalence 46%
Stigma affects nearly half of adults with SLE, pooled prevalence 46%Nearly half of people with lupus face social stigma
LupusPublished October 2, 2026Study authors: Abdulazeem Hebatullah M, Bellakhal Syrine, Abida Rym, Soliman SaeedPubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize that nearly half of SLE patients may experience stigma; screen for it.
This meta-analysis synthesized observational data on the prevalence and determinants of stigma among adults living with systemic lupus erythematosus, with a pooled sample of 2254 participants. The authors examined interpersonal, perceived, and intrapersonal stigma and their associations with mental health.
The pooled overall burden of stigma was moderate, with an effect size of 34.71 (95% CI 26.15, 43.27). Nearly one in two persons, 46% (95% CI 28-66%), reported experiencing at least one form of stigma or discrimination.
The review notes that stigma and discrimination act as toxic stressors creating a cycle with psychological stress and disease activity. However, because this is a meta-analysis of observational studies, these findings should be interpreted as associations rather than direct causation.
Limitations were not reported, and certainty of evidence was not reported. The authors highlight a need for healthcare management teams to screen for the invisible burden of invalidation and discrimination in SLE patients. Practice relevance centers on awareness and screening rather than a specific intervention.
How this fits prior evidence
This meta-analysis extends prior coverage of SLE by shifting focus from biomarkers and therapies to the psychosocial burden of stigma. Prior items addressed CSF IL-6 and MCP-1 for neuropsychiatric involvement, telitacicept for SRI-4 response, EHR algorithms for identification, exercise for fatigue, and targeted therapies for disease activity. The current synthesis addresses a gap in quantifying stigma prevalence, reporting that 46% experienced at least one form of stigma or discrimination. It does not confirm or contrast with those prior findings directly, but adds a patient-experience dimension to the existing clinical evidence base.
Living with systemic lupus erythematosus (SLE) is hard enough on its own. However, many patients face an invisible hurdle: the weight of social stigma and discrimination. New data shows that nearly one in two people living with this condition experience at least one form of stigma or discrimination.
Researchers looked at data from over 2,000 adults with lupus. They found a moderate overall burden of stigma, which can create a cycle of stress. This stress can make it harder to manage the physical symptoms of the disease. The study highlights how these social pressures can impact a person's mental well-being.
Because these experiences are often hidden, they can be hard for doctors to spot. The findings suggest that healthcare teams should look closer at the emotional toll of discrimination. While the study shows a strong link between stigma and stress, it is important to remember these are associations rather than direct causes.
What this means for you:
Nearly half of people with lupus face stigma, which can create a cycle of stress and impact mental health.
Common questions
How common is stigma among people with lupus?
The data shows that nearly one in two people living with systemic lupus erythematosus experience at least one form of stigma or discrimination. This means about 46 percent of people in the study faced these social challenges.
How does stigma affect someone with lupus?
Stigma and discrimination act as toxic stressors. These experiences can create a cycle of psychological stress and increased disease activity, making it harder for patients to manage their condition.
What does this mean for healthcare?
The findings suggest that healthcare teams should screen for the invisible burden of invalidation and discrimination. This helps doctors identify the mental health impacts that social stigma has on patients.
BackgroundSystemic lupus erythematosus (SLE) is a complex autoimmune disease with 0.4 million new cases diagnosed annually. With its wide variety of visible and invisible manifestations, people living with SLE report being exposed to stigmatization, which impacts their personal and professional lives. However, the current literature is unclear on whether healthcare management teams assess this concern during follow-up. This study aims to synthesize existing evidence on the prevalence and determinants of stigma among people living with SLE.MethodsThis systematic review and meta-analysis gathered evidence from observational studies identified from three databases on 16 July 2025. Dual independent screening, data extraction, and risk-of-bias assessment (using the Newcastle-Ottawa Scale) were performed. Results were synthesized using descriptive statistics, narrative synthesis, and indicator-level meta-analyses.ResultsWithin the past two decades, 11 studies comprising 2254 people living with SLE reported and measured stigma- and discrimination-related events using various scales. Stigma was found to be prevalent across its three constructs: interpersonal, perceived, and intrapersonal stigma. This review demonstrated that people living with SLE reported a moderate overall burden of stigma (34.71 [95% CI 26.15, 43.27]), with average stigma scores indicating psychological impact. Additionally, nearly one in two persons (46% [95% CI 28-66%]) experienced at least one form of stigma or discrimination, most commonly social isolation and unfair treatment. Mental health associations were correlated with higher stigma burden.ConclusionThis review demonstrates that stigma and discrimination are not just social challenges but also critical determinants of health. With cautious interpretation, pooled evidence reveals a consistent high prevalence of stigma and discrimination, which act as "toxic" stressors, creating a vicious cycle with psychological stress and psychiatric manifestations and disease activity. There is an urgent clinical need to move beyond a mere biological approach to disease assessment and management and to begin screening for the "invisible" burden of invalidation and discrimination.
